ImmunsanT announces end of its global Phase 2 clinical trial for its Nexvax2 drug candidate. Early results indicate gluten-exposure protection similar to placebo.
ImmusanT, a biotechnology company focusing on protecting patients with celiac disease against the effects of gluten, has announced that it has secured $40 million in funding to advance its drug,…
ImmusanT, a clinical-stage company developing Nexvax2®, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet, presented data at the 2017 International Celiac Disease…
ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial…
On behalf of our patient community, CDF has either directly invested or fought to secure investments in diagnostics, research, and treatment for celiac disease. We have always known that this was a serious disease with broad and often devastating impacts if left undiagnosed and/or untreated. Our 25 years of hard work continues to yield returns. This is from a NY Times article published on April 29, 2015, "Pharmaceutical companies are racing to develop the first drugs for celiac disease, which researchers say is much more common than previously thought."
New drugs on the research horizon could spare people with celiac the pain of accidentally eating pizza or pasta. Even with the best intentions, living gluten-free is much easier said than done. It was almost impossible to tell which packaged “gluten-free” foods lived up to their claims until late last year when the U.S. Food and Drug Administration (FDA) began enforcing gluten-free labeling guidelines. And it's hard to guarantee you won’t accidentally consume gluten at a restaurant or on an occasion, such as a well-meaning relative’s dinner party.
Currently, the typical treatment for a patient diagnosed with celiac disease is a strict gluten-free diet for life. Future therapies currently in the pipeline hope to make living with celiac disease less of a burden.
[video width="600" height="200" mp4="/wp-content/uploads/2024/09/ICDS-2024-header-recap.mp4" poster="/wp-content/uploads/2024/09/ICDS-2024-header-recap.jpg"][/video] Last month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with...